Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia

被引:4
|
作者
Benites, Bruno Deltreggia [1 ]
Traina, Fabiola [1 ]
Santos Duarte, Adriana da Silva [1 ]
Lorand-Metze, Irene Gyongyver H. [1 ]
Costa, Fernando Ferreira [1 ]
Saad, Sara Teresinha [1 ]
机构
[1] Univ Estadual Campinas, Dept Internal Med, Hematol & Hemotherapy Ctr, BR-13083970 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
apoptotic protease-activating factor 1 (APAF-1); myelodysplastic syndrome; apoptosis; DEPENDENT APOPTOSIS; CELLS; PROGENITORS; MELANOMA; CANCER;
D O I
10.1111/j.1600-0609.2010.01429.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: APAF-1 is a central component of the intrinsic pathway of apoptosis, where APAF-1 dysregulation results in the development of diverse human neoplasms. The aim of this study was to characterize the mRNA expression levels of APAF-1 transcripts in low-risk and high-risk MDS and to elucidate whether the expression levels of APAF-1 transcripts are modulated with increased apoptosis in CD34+ MDS cells undergoing erythroid differentiation. Methods: APAF-1 (NM_181861) expression was verified, by quantitative RT-PCR, in bone marrow aspirates from 33 patients with myelodysplastic syndromes (MDS), at the time of diagnosis, and in erythroid differentiation cultures from CD34+ from normal donors and patients with MDS. Results: APAF-1 expression was significantly higher in low-risk, compared to high-risk MDS, according to IPSS (P < 0.0001), FAB (P = 0.0265), and cytogenetic risk (P = 0.0134). Low-risk MDS-derived differentiated erythroid cells demonstrated an increased expression of APAF-1, compared with normal cells, accompanied by an augmented rate of apoptosis. Conclusions: Increased expression of APAF-1 in low-risk disease and its positive correlation with the apoptotic rate observed during the erythroblast differentiation of low-risk MDS cells may indicate that the modulation of APAF-1, at the transcriptional level, participates in the pathophysiology of MDS.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 50 条
  • [31] Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
    Baron, Frederic
    Suciu, Stefan
    Amadori, Sergio
    Muus, Petra
    Zwierzina, Heinz
    Denzlinger, Claudio
    Delforge, Michel
    Thyss, Antoine
    Selleslag, Dominik
    Indrak, Karel
    Ossenkoppele, Gert
    de Witte, Theo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 529 - 533
  • [32] Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome
    Zhang, Zheng
    Chang, Chun-Kang
    He, Qi
    Guo, Juan
    Tao, Ying
    Wu, Ling-Yun
    Xu, Feng
    Wu, Dong
    Zhou, Li-Yu
    Su, Ji-Ying
    Song, Lu-Xi
    Xiao, Chao
    Li, Xiao
    LEUKEMIA & LYMPHOMA, 2017, 58 (04) : 969 - 978
  • [33] Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes
    M del Rey
    K O'Hagan
    M Dellett
    S Aibar
    H A A Colyer
    M E Alonso
    M Díez-Campelo
    R N Armstrong
    D J Sharpe
    N C Gutiérrez
    J L García
    J De Las Rivas
    K I Mills
    J M Hernández-Rivas
    Leukemia, 2013, 27 : 610 - 618
  • [34] Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes
    del Rey, M.
    O'Hagan, K.
    Dellett, M.
    Aibar, S.
    Colyer, H. A. A.
    Alonso, M. E.
    Diez-Campelo, M.
    Armstrong, R. N.
    Sharpe, D. J.
    Gutierrez, N. C.
    Garcia, J. L.
    De Las Rivas, J.
    Mills, K. I.
    Hernandez-Rivas, J. M.
    LEUKEMIA, 2013, 27 (03) : 610 - 618
  • [35] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Muzeyyen Aslaner Ak
    Birsen Sahip
    Ayfer Geduk
    Mehmer Ali Ucar
    Hacer Kale
    Tugba Hacibekiroglu
    Merve Gokcen Polat
    Yasin Kalpakci
    Ali Zahit Bolaman
    Birol Guvenc
    Sehmus Ertop
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 299 - 308
  • [36] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Ak, Muzeyyen Aslaner
    Sahip, Birsen
    Geduk, Ayfer
    Ucar, Mehmer Ali
    Kale, Hacer
    Hacibekiroglu, Tugba
    Polat, Merve Gokcen
    Kalpakci, Yasin
    Bolaman, Ali Zahit
    Guvenc, Birol
    Ertop, Sehmus
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 299 - 308
  • [37] EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients
    Liu, Lin
    Wang, Jinhuan
    Jiang, Yanan
    Xie, Huan
    Tang, Xiaoqiong
    Li, Qiubai
    Wang, Huaquan
    Zou, Ping
    Miao, Zhaoyi
    Lv, Yangyang
    Wang, Haitao
    Cao, Zeng
    Zhao, Zhigang
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2929 - 2940
  • [38] Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate-1 risk patients with myelodysplastic syndromes
    Kalitin, Nikolay
    Dudina, Galina
    Kostritsa, Natalia
    Sivirinova, Anastasiya
    Karamysheva, Aida
    ONCOLOGY LETTERS, 2023, 25 (03)
  • [39] GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da
    Yang, Shujun
    Gao, Tong
    Zheng, Zhonghua
    Lai, Binbin
    Sheng, Lixia
    Xu, Zhijuan
    Yan, Xiao
    Wang, Jiaping
    Duan, Shiwei
    Ouyang, Guifang
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (09)
  • [40] Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?
    Nakao, S.
    Gale, R. P.
    LEUKEMIA, 2016, 30 (11) : 2127 - 2130